We’re excited to share the latest updates to enhance your Science42: #DORA experience: ?? Trial Document Generation -Trial users can now generate up to 3 free documents to explore DORA’s capabilities before committing to a subscription. ?? Enhanced Editing -Automatically remove deleted citations from the Bibliography list and exported files. -Bibliography Cleanup ensures your references stay accurate and organized. ?? Transparency logs Improvements -Transparency now reflects the correct generation order for better clarity. -New statuses: "In Progress" and "Complete" for document generation tracking. -Additional agent actions provide deeper insights into the content creation process. ?? Performance Boost -Optimized web search and file upload performance with improved embedding token handling. -Token consumption is now included in the weekly statistics report for easier usage monitoring. Get started today ?? https://pharma.ai/dora #AIGeneration #DocumentGenerator #Publications
Insilico Medicine
生物技术研究
Boston，Massachusetts 59,760 位关注者
#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity
关于我们
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
- 网站
-
https://www.Insilico.com
Insilico Medicine的外部链接
- 所属行业
- 生物技术研究
- 规模
- 201-500 人
- 总部
- Boston，Massachusetts
- 类型
- 私人持股
- 创立
- 2014
- 领域
- artificial intelligence、deep learning、reinforcement learning、drug discovery、aging research、longevity、biomarker development、Generative adversarial networks、GANs和GANs-RL
地点
Insilico Medicine员工
动态
-
Black Friday Special from Insilico Medicine?? Science42: #DORA is now available to new users for 50% off, available through December 3. Unlock the future of scientific writing with DORA (Draft Outline Research Assistant), an advanced #AI-driven tool designed to streamline the process of drafting academic papers and other related documents. Get started today! Only available for a limited time: https://bit.ly/4fZcT88 #DocumentGeneration #GenerativeAI #Publications #ConferenceAbstracts #ReviewWriting #Blogs
-
-
?? ?? Congratulations to Alex Zhavoronkov on this incredible achievement from Clarivate!
Thank you, Clarivate and thanks to my team for turning some dreams in biology, chemistry and even in clinical trials into reality. From the very inception of Insilico we committed to making our work as transparent as commercially possible. Most of our AI is commercially-available. Get your Pharma.AI suite from Petrina Kamya, Ph.D. today! https://lnkd.in/guC4TjN8
-
-
https://lnkd.in/emDmHryb ?? Thank you to Endeavor Venture Fund & Venture Studio Group and Mount Sinai Health System for hosting the #AIHealthcare Summit! Our CBO, Michelle Chen, took home the Showcase #AI and Biotech Innovation Award. Congratulations to Michelle and all the winning companies!
-
Please join Flare Capital Partners for the next virtual expert roundtable as we delve into the evolving landscape of longevity. The expert speakers will explore the latest advancements in longevity science, the role of technology in promoting sustained health, and the innovative approaches startups are taking to redefine the concept of aging. Hear from CEO, Alex Zhavoronkov, PhD, on December 3! Register today: https://bit.ly/3CWjRw2 #longevity #longevityevents
-
-
Join us on December 12 for an exclusive deep dive into the transformative role of AI in biotech innovation. ?? Hosted by Insilico Medicine and GenAI4Pharma, this event will feature discussions on cutting-edge advancements, including AI-powered drug discovery, platform highlights, and real-world impact. ?? What to expect: Insights from top experts in AI and life sciences Demos of our groundbreaking platforms, including PandaOmics, Chemistry42, and Science42 Live Q&A to explore your questions ?? Save Your Spot Now: https://bit.ly/4imh1RB Don’t miss out on this opportunity to engage with industry leaders and stay ahead in biotech innovation! ? #GenAI4Pharma is a global series of events that showcases the application of GenerativeAI, LLMs and related technologies in the biopharma industry, across the biopharma value chain, including: R&D, Clinical, Medical, Commercialization, etc.
-
-
?? Announcing the latest publication from ACS Publications, and the JAMCDD Journal: Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer Abstract: Hematopoietic progenitor kinase 1 (HPK1) has emerged as an attractive target for immunotherapy due to its critical role in T cell activation and proliferation. The major challenge in developing HPK1 inhibitors lies in balancing kinase selectivity, pharmacokinetic (PK) properties, and therapeutic efficacy. In this study, we report a series of pyridine-2-carboxamide analogues demonstrating strong HPK1 inhibitory activity in enzymatic and cellular assays, along with good kinase selectivity. Among these analogues, compound?19?showed good in vitro HPK1 inhibitory activity, excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK), and robust in vivo efficacy in the CT26 (tumor growth inhibition (TGI) = 94.3%, 2/6 CRs) and MC38 murine colorectal cancer models (TGI = 83.3%, 1/6 complete response) when administered in combination with anti-PD-1. Compound?19?also demonstrated adequate in vitro ADME and in vivo PK properties, displaying good oral bioavailability across multiple species (F?% = 35–63). These findings summarize our compound’s favorable safety and efficacy profiles, justifying its testing in future translational studies. Check out the full publication here: https://lnkd.in/eZX_sZrV #MedicinalChemistry #Pharmacokinetic #efficacy #cancertreatment
Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer
pubs.acs.org
-
Join us at #GenAI4Pharma in Cambridge in just a few weeks! Stay up-to-date on the application of #GenAI and #LLM technologies at this upcoming event. Registration details are below ??
Digital Health and Corporate Innovation Executive | Independent Consultant working with Startups and Corporate | ex-Novartis BIOME co-founder | Startup Investor, Advisor & Mentor | Founder of #GenAI4Pharma
?? Only 3 weeks to go till #GenAI4Pharma: #Cambridge (USA)! ?? Register now for the 5th installment of the global event series focused on the application of #GenAI and #LLM-related technologies for the #biopharma industry, across the value chain, including: R&D, #Clinical, #Medical and #Commercial. ? #Date: December 12th, 2024 ? #Registration: https://lu.ma/hn9mku85 ? #Details: https://GenAI4Pharma.com ? #Venue: Insilico Medicine (Cambridge, MA) — https://lnkd.in/ekuejT89 ? Don't miss your chance to hear from the following thought leaders: ? #FeaturedKeynote:?"Generative Al and the Future of #DrugDevelopment — A New Era of Al-Designed #IPF Therapy" ?—??Carol Ann Satler, MD, PhD (Insilico Medicine) ? #PharmaPanel: ?—??Michelle Chen?(Insilico Medicine) ?—??John Chan?(Takeda) ?—??Sandeep Burugupalli?(Novo Nordisk) ? #InvestorPanel: ?—??Sofia Guerra?(Bessemer Venture Partners) ? #StartupPanel: ?—??Jean-Frederic Petit-Nivard?(Owkin) ?—??Ravi Ramachandran?(Peer AI) ? #ResponsibleAI & #PatientPanel: ??—?Jen Horonjeff?(Savvy Cooperative) ?—?Todd Quartiere?(Foundation for AI & Health (FAIH) ?? The event will also include a #StartupPitch Session featuring startups that are building #GenAI applications for the #biopharma industry — if you're a startup in this space, apply to pitch now in front of an audience of #BioPharma #Executives, #Investors, #TechCos, #Startups, etc.: https://lnkd.in/e5vdUaYP. ?? #SponsorshipOpportunities: We're looking for like-minded event partners, interested in showcasing the transformative power and growing the ecosystem for #GenAI in the biopharma industry, so if you're interested in sponsoring the event, please DM me. cc: Thomas L., Alex Zhavoronkov, Sooah Cho, Anita Modi, Christopher Ceppi, @
-
-
??New longevity speaker announcements! The topic of hashtag #longevity is generating a lot of buzz in healthcare — and for good reason. With rapid advancements and big claims about extending the human lifespan, it's a topic on everyone's radar. But what's the real story behind the science, and how are healthcare organizations and innovators navigating this emerging field? Please join Flare Capital Partners for our next virtual expert roundtable as we delve into the evolving landscape of longevity. Our expert speakers will explore the latest advancements in longevity science, the role of technology in promoting sustained health, and the innovative approaches startups are taking to redefine the concept of aging. We are excited to dig into these topics with?leaders who are innovating and investing for a longer, healthier life: ? Lance Armstrong, Founder & Managing Partner, NEXT VENTūRES ? Hillary Lin, MD, Founder, Livora Health ? Robin Berzin MD, Founder & CEO, Parsley Health ? Pranitha Patil, Co-Founder & COO, Function Health ? Alex Zhavoronkov, Founder & CEO, Insilico Medicine ???? Register Here: https://lnkd.in/ehSpqdXd
-